Otto Simonsson
Researcher in Clinical Neuroscience at Karolinska Institute
Data updated
Research Footprint
Otto Simonsson appears in 22 tracked papers (2021–2026), most studied alongside Psilocybin, Ayahuasca and DMT, across Substance Use Disorders (SUD), Depressive Disorders and Anxiety Disorders.
Most-cited paper: Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics (124 citations).
Frequent co-authors: Peter Hendricks, Wojciech Osika and Samuel Goldberg.
Publication Landscape
How the 22 papers Blossom tracks for Otto Simonsson line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Otto Simonsson's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 22 of 22 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Otto Simonsson publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Otto Simonsson publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Otto Simonsson is a Swedish researcher whose work examines the prevalence of mental health outcomes associated with naturalistic psychedelic use. He investigates how individual factors, such as a family history of mental illness, influence the response to psychedelics. His research aims to provide a more nuanced understanding of safety and risk profiles for psychedelic medicine in diverse populations.
Key Impact
Explores the psychiatric risks and benefits of psychedelic use, focusing on genetic and environmental factors.
Collaboration Network
41 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Otto Simonsson's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Otto Simonsson is associated with.